Before the diagnosis of LM, ten patients had undergone systemic therapy with EGFR-tyrosine kinase inhibitor (TKI) or pemetrexed, and the patient with ALK rearrangement had undergone treatment with systemic ALK inhibitor and bevacizumab (Table 1). This evidence concerns the gene EGFR and lymphangioma.